Literature DB >> 21455199

Molecular analysis of thyroid tumors.

Yuri E Nikiforov1.   

Abstract

In the recent years, a large number of molecular alterations in thyroid cancer has been discovered and characterized. Some of these markers may have significant diagnostic utility, can be used for tumor prognostication, and serve as potential therapeutic targets. The diagnostic utility of these markers is of particular importance in thyroid fine-needle aspiration samples. Some molecular markers, such as BRAF, offer help in risk stratification and can be potentially used to optimize surgical and postsurgical management of patients with thyroid cancer. This review discusses major molecular alterations known to occur in thyroid cancer, focusing on those markers that have been extensively characterized, carry clinical significance, and are being introduced into pathology practice.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21455199     DOI： 10.1038/modpathol.2010.167

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


  52 in total

Review 1.  Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain.

Authors:  Virginia A LiVolsi; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2011-12       Impact factor: 3.943

Review 2.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

3.  BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Adrian J Correa; Jonathan S LoPresti; Alan L Epstein
Journal:  Thyroid       Date:  2014-07-15       Impact factor: 6.568

4.  Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.

Authors:  Andrey Bychkov; Vladimir Saenko; Masahiro Nakashima; Norisato Mitsutake; Tatiana Rogounovitch; Alyaksandr Nikitski; Florence Orim; Shunichi Yamashita
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

5.  Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.

Authors:  Matthias Dettmer; Aurel Perren; Holger Moch; Paul Komminoth; Yuri E Nikiforov; Marina N Nikiforova
Journal:  Thyroid       Date:  2013-09-19       Impact factor: 6.568

6.  Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Authors:  Patricia Aragon Han; Hyun-seok Kim; Soonweng Cho; Roghayeh Fazeli; Alireza Najafian; Hunain Khawaja; Melissa McAlexander; Benzon Dy; Meredith Sorensen; Anna Aronova; Thomas J Sebo; Thomas J Giordano; Thomas J Fahey; Geoffrey B Thompson; Paul G Gauger; Helina Somervell; Justin A Bishop; James R Eshleman; Eric B Schneider; Kenneth W Witwer; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2016-03-07       Impact factor: 6.568

Review 7.  Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

8.  Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.

Authors:  Christelle de la Fouchardiere; Nadia Oussaid; Olfa Derbel; Myriam Decaussin-Petrucci; Marie-Eve Fondrevelle; Qing Wang; Pierre-Paul Bringuier; Claire Bournaud-Salinas; Jean-Louis Peix; Jean-Christophe Lifante; Anne-Laure Giraudet; Jonathan Lopez; Françoise Borson-Chazot
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

9.  Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.

Authors:  G Pentheroudakis; E A Kotteas; V Kotoula; K Papadopoulou; E Charalambous; A Cervantes; T Ciuleanu; G Fountzilas; N Pavlidis
Journal:  Clin Exp Metastasis       Date:  2014-07-05       Impact factor: 5.150

10.  Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (case-control study).

Authors:  Mosin S Khan; Arshad A Pandith; Mahboob Ul Hussain; Mohammad Iqbal; Nighat P Khan; Khurshid A Wani; Shariq R Masoodi; Syed Mudassar
Journal:  Tumour Biol       Date:  2012-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.